Dr. Nasim Mayeli | cell therapy | Best Researcher Award

Dr. Nasim Mayeli | cell therapy | Best Researcher Award

Research Assistant at cell therapy , Shahid chamran university, Iran

Nasim Mayeli Fereydani earned her Ph.D. in Molecular Genetics from Shahid Chamran University in Ahvaz, Iran. Her doctoral research, conducted from 2016 to 2024, centered on correcting the Beta-globin CD36/37(-T) mutation in human hematopoietic stem cells using the CRISPR/Cas9 platform. Dr. Fereydani’s work was conducted under the guidance of Dr. Hamid Galehdari, a Professor in Molecular Genetics.

Professional Profiles:

EDUCATION:

Nasim Mayeli Fereydani has a diverse academic background, starting with a B.Sc. in Microbiology from Shahid Chamran University in Ahvaz, Iran, completed from 2003 to 2007. She then pursued an M.Sc. in Microbiology at the same university, completing her thesis on the isolation of polyhydroxyalkanoates-producing bacteria from contaminated soil of Bandar Imam Petrochemical Industries under the supervision of Dr. Hossein Motamedi, a Professor in Microbiology, from 2009 to 2012. Nasim furthered her studies with a Ph.D. in Molecular Genetics at Shahid Chamran University, focusing her research on correcting the Beta-globin CD36/37(-T) mutation in human hematopoietic stem cells using the CRISPR/Cas9 platform. Her doctoral thesis was supervised by Dr. Hamid Galehdari, a Professor in Molecular Genetics, and she completed her Ph.D. from 2016 to 2024.

WORK EXPERIENCE:

Nasim Mayeli Fereydani has been actively involved in various educational, community, clinical, and research activities. As a Lecturer at Islamic Azad University Ahvaz Branch from 2021 to 2023, she taught courses on Principles of Genetics, Cancer Genetics, Genetic Engineering Laboratory, Basic Genetic Laboratory, and Cell Culture. In addition, she participated in professional community activities, focusing on disability awareness and prevention plan and familiarization with genetic counseling for students of Ahvaz, Iran-National Welfare Organization, from 2017 to 2018. In clinical settings, Nasim worked at Ghandil Medical Genetics Laboratory from 2013 to 2017. She served as the Supervisor and technical technician of the prenatal diagnostic of thalassemia department from 2015 to 2017, the technical technician of the molecular department from 2014 to 2017, and the technical technician of the cytogenetics department, involved in karyotyping, from 2013 to 2014. Furthermore, Nasim was a Research Assistant at Ahvaz Jundishapur University of Medical Sciences from 2011 to 2013. She collaborated on research projects in the faculty of medicine, department of immunology, student and research projects in the faculty of dentistry, and the research project of the thalassemia & hemoglobinopathy research center from 2019 to 2023.

SKILLS:

Nasim Mayeli Fereydani has a wide range of skills in both wet and dry lab techniques. In the wet lab, she is proficient in DNA and RNA extraction from various sources, including blood, cell lines, and bacteria. She has expertise in various PCR techniques, such as Conventional PCR, Real-time PCR (SYBR Green -TaqMan), ARMS-PCR, Multiplex-PCR, and PCR-RFLP. Nasim is also skilled in electrophoresis using agarose gel and Polyacrylamide (PAGE), with experience in silver nitrate staining. She is knowledgeable in cloning methods, including Conventional cloning and TA-cloning, as well as gene editing using CRISPR/Cas9. Nasim has experience in bacterial culture, mammalian cell culture (including cancer cell lines like A549, MCF7, HepG2, and HEK293T), and stem cell culture (isolating mesenchymal stem cells from various tissues and hematopoietic stem cells using immunomagnetic separation). She is also familiar with flow cytometry (sample preparation, instrument setting, and data analysis using FlowJo), fluorescent microscopy, cell transfection methods (Nucleofection and polyethylenimine), and laboratory animal handling (injection of cancer cells to create mouse models).  In the dry lab, Nasim is skilled in primer and probe design for guide RNA and Donor DNA, statistical analysis using SPSS, and proposal writing.

PUBLICATIONS:

Mayeli N, Motamedi H, Heidarizadeh F. “Production of Polyhydroxybutyrate by Bacillus axaraqunsis BIPC01 using Petrochemical Wastewater as Carbon Source.” Braz arch biol technol. 2015:643-50

Motamedi H, Roayaee Ardakani M, Mayeli N. “Isolation and screening of native polyhydroxyalkanoate producing bacteria from oil contaminated soils of Abadan refinery.” Biological Journal of Microorganism. 2015;3(12):93-104.

Mayeli N, Galehdari H, Hoveizi E, Ajami M. “A comparison of the efficiency of the T7-Endonuclease I enzyme and polyacrylamide gel electrophoresis system in evaluating the cleavage efficiency of the CRISPR/Cas9 system.” Journal of Isfahan Medical School. 2024.

Mayeli N, Galehdari H, Hoveizi E, Ajami M, Alghasi A. “Ex vivo expansion of Hematopoietic stem cells in two/three-dimensional co-cultures with various sources of stromal cells.” Tissue and Cell journal, 2024 (accepted/in press).

“Genetic correction of CD 36/37 (-T) β-thalassemia mutation by CRISPR/Cas9 in human hematopoietic stem cells as a common mutation of southwest of Iran” (under preparation).

 

 

Dr. Liton Kumar Saha | Cancer | Excellence in Research

Dr. Liton Kumar Saha | Cancer | Excellence in Research

Post-doctoral Fellow at Cancer, National Cancer Institute, United States

👨‍🎓He remarkable academic journey, extensive research contributions, and dedication to the field of psychology are truly commendable. Your wealth of knowledge and diverse skill set reflect a deep commitment to understanding and addressing critical issues such as bullying, inclusion, and socialization.

🔬 He successful completion of a PhD in Psychology, along with the numerous advanced courses and workshops, showcases your continuous pursuit of excellence and expertise in your field.

🏆 The awards and recognitions, including the First Place in the Poster Award at the University of Stavanger, underscore the impact of your research and the high regard it holds in the academic community.

Professional Profiles:

Education/Research:

From July 2019 to the present, [Name] has served as a Postdoctoral Fellow (Visiting) at the Developmental Therapeutics Branch, National Cancer Institute, NIH. His research focuses on PARP1, TOP3A, Replication, DNA repair, DNA-protein crosslink, mitochondria, and related topics. He earned his Ph.D. degree in Medical Sciences from the Graduate School of Medicine, Kyoto University, Kyoto, Japan, from 2016 to 2019. His Ph.D. research was conducted in the Department of Radiation Genetics, where he investigated the novel function of genes in DNA repair and DNA damage tolerance. He achieved this by generating mutants in human cell lines using CRISPR/Cas9 and TALEN technology. Prior to his Ph.D., he completed his Master’s degree in medical sciences at the Graduate School of Medicine, Kyoto University, Kyoto, Japan, from 2014 to 2016. His research during this period focused on DNA repair and toxicology, specifically utilizing DNA-repair-deficient cells to identify genotoxins with greater sensitivity and characterizing DNA lesions caused by industrial chemical compounds. He received his Master’s degree in Biochemistry and Molecular Biology from the Faculty of Biological Sciences, University of Dhaka, Dhaka, Bangladesh, in 2007-2008. His dissertation was on the phenotypic and molecular characterization of Salmonella Typhi isolated recently in Bangladesh. He also holds a Bachelor’s degree in Biochemistry and Molecular Biology from the Faculty of Biological Sciences, University of Dhaka, Dhaka, Bangladesh, achieved with distinction, from 2001 to 2006.

🔬 Visiting Research Associate

  • Dr. Samuel H. Wilson lab
  • Genome Integrity and Structure Biology Laboratory
  • National Institute of Environmental Health Sciences (NIEHS), NIH, USA
  • March 2017-May 2017
  • Research Topic: Established In-vitro base excision repair (BER) of CPD lesion-containing DNA (cell-extract based and enzyme-mediated both).

🔬 Visiting Research Associate

  • Professor Ian D Hickson lab
  • Center for Chromosome Stability
  • Institute of Cellular and Molecular Medicine
  • Faculty of Health and Medical Sciences
  • University of Copenhagen, Copenhagen, Denmark
  • September 2015- November 2017
  • Research Topic: Performed and established the protocol for the detection of ultrafine DNA bridges (UFBs) in human TK6 cells using MRE11 mutant.

🔬 Research Assistant

  • Department of Radiation Genetics
  • Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • August 2013- March 2014

🔬 Research Officer

  • International Center for Diarrheal Diseases Research, Bangladesh (ICDDR, B)
  • Dhaka, Bangladesh
  • 2009-2012

Awards:

During the period of 2014 to 2019, [Name] was awarded a Scholarship from the Training Program of Leaders for Integrated Medical System: for Fruitful Healthy-Longevity Society in Japan. Additionally, in 2018, he received a research grant from the Training Program of Leaders for Integrated Medical System at Kyoto University, Japan. Similarly, in both 2017 and 2016, he was also awarded research grants from the same Training Program at Kyoto University, Japan.

Publications:

  1. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II–DNA complexes
    • Authors: H Sasanuma, M Tsuda, S Morimoto, LK Saha, MM Rahman, Y Kiyooka, …
    • Citations: 81
    • Year: 2018
  2. Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC)
    • Authors: Y Sun, S Saha, W Wang, LK Saha, SYN Huang, Y Pommier
    • Citations: 72
    • Year: 2020
  3. Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents
    • Authors: U Jo, IS Senatorov, A Zimmermann, LK Saha, Y Murai, SH Kim, …
    • Citations: 64
    • Year: 2021
  4. Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways
    • Authors: Y Sun, LK Saha, S Saha, U Jo, Y Pommier
    • Citations: 56
    • Year: 2020
  5. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
    • Authors: U Jo, Y Murai, S Chakka, L Chen, K Cheng, J Murai, LK Saha, …
    • Citations: 34
    • Year: 2021
  6. Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1–DNA complexes
    • Authors: LK Saha, Y Murai, S Saha, U Jo, M Tsuda, S Takeda, Y Pommier
    • Citations: 22
    • Year: 2021
  7. Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells
    • Authors: LK Saha, M Wakasugi, S Akter, R Prasad, SH Wilson, N Shimizu, …
    • Citations: 21
    • Year: 2020
  8. The ARK assay is a sensitive and versatile method for the global detection of DNA-protein crosslinks
    • Authors: Q Hu, N Klages-Mundt, R Wang, E Lynn, LK Saha, H Zhang, M Srivastava, …
    • Citations: 21
    • Year: 2020
  9. UBC13-mediated ubiquitin signaling promotes removal of blocking adducts from DNA double-strand breaks
    • Authors: R Akagawa, HT Trinh, LK Saha, M Tsuda, K Hirota, S Yamada, A Shibata, …
    • Citations: 18
    • Year: 2020

 

 

Mr. Liang Gong | Cancer Targeting Treatment | Best Researcher Award

Mr. Liang Gong | Cancer Targeting Treatment | Best Researcher Award

Post Doctor at Cancer Targeting Treatment , Shenzhen Institute of Advanced Technology, China

👨‍🎓He remarkable academic journey, extensive research contributions, and dedication to the field of psychology are truly commendable. Your wealth of knowledge and diverse skill set reflect a deep commitment to understanding and addressing critical issues such as bullying, inclusion, and socialization.

🔬 He successful completion of a PhD in Psychology, along with the numerous advanced courses and workshops, showcases your continuous pursuit of excellence and expertise in your field.

🏆 The awards and recognitions, including the First Place in the Poster Award at the University of Stavanger, underscore the impact of your research and the high regard it holds in the academic community.

Professional Profiles:

Education:

Mr. Liang Gong pursued his education in biotechnology, earning a Ph.D. from Jiangnan University in Wuxi, Jiangsu, CN (2019-09-06 to 2023-06-13) from the School of Biotechnology. Prior to this, he obtained an MD from Hunan Normal University in Changsha, Hunan, CN (2016-09 to 2019-06) with a focus on the State Key Laboratory of Developmental Biology of Freshwater Fish, Hunan Provincial Key Laboratory of Microbial Molecular Biology, College of Life Science. 😊

Patent & Funding:

Mr. Liang Gong is the inventor of the patent “Ligand-Targeted Cell Conjugate (Ltcc)-Based Anti-Tumor Immune Cell, As Well As Preparation Method And Use Thereof” with the registration number US 17551412. Additionally, he has received funding from the Postgraduate Research and Practice Innovation Program of Jiangsu Province (KYCX21_2021).

Publications:

Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer

An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy

ELOA promotes tumor growth and metastasis by activating RBP1 in gastric cancer

EXOSC8 promotes colorectal cancer tumorigenesis via regulating ribosome biogenesis-related processes

A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer

Hyaluronic Acid-Coated Bovine Milk Exosomes for Achieving Tumor-Specific Intracellular Delivery of miRNA-204

Ferroptosis-Associated Molecular Features to Aid Patient Clinical Prognosis and Therapy Across Human Cancers

β-Galactosidase-dependent metabolic glycoengineering of tumor cells for imaging and immunotherapy

Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy

Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy